Open access · CC-BY
via OpenAlex
Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease
Lars Tatenhorst, Katrin Eckermann, Vivian Dambeck, Luis Fonseca‐Ornelas, Hagen Walle, Tomás Lopes da Fonseca, Jan Christoph Koch, Stefan Becker, Lars Tönges, Mathias Bähr, Tiago F. Outeiro, Markus Zweckstetter, Paul Lingor
Acta Neuropathologica Communications · 2016 · ▲ 162 citations
Abstract
Parkinson's disease (PD) is the most common neurodegenerative movement disorder, yet disease-modifying treatments do not currently exist. Rho-associated protein kinase (ROCK) was recently described as a novel neuroprotective target in PD. Since alpha-synuclein (α-Syn) aggregation is a major hallmark in the pathogenesis of PD, we aimed to evaluate the anti-aggregative potential of pharmacological ROCK inhibition using the isoquinoline derivative Fasudil, a small molecule inhibitor already approved for clinical use in humans. Fasudil treatment significantly reduced α-Syn aggregation in vitro in a H4 cell culture model as well as in a cell-free assay. Nuclear magnetic resonance spectroscopy analysis revealed a direct binding of Fasudil to tyrosine residues Y133 and Y136 in the C-terminal region of α-Syn. Importantly, this binding was shown to be biologically relevant using site-directed mutagenesis of these residues in the cell culture model. Furthermore, we evaluated the impact of long-term Fasudil treatment on α-Syn pathology in vivo in a transgenic mouse model overexpressing human α-Syn bearing the A53T mutation (α-Syn(A53T) mice). Fasudil treatment improved motor and cognitive functions in α-Syn(A53T) mice as determined by Catwalk(TM) gait analysis and novel object recognition (NOR), without apparent side effects. Finally, immunohistochemical analysis revealed a significant reduction of α-Syn pathology in the midbrain of α-Syn(A53T) mice after Fasudil treatment. Our results demonstrate that Fasudil, next to its effects mediated by ROCK-inhibition, directly interacts with α-Syn and attenuates α-Syn pathology. This underscores the translational potential of Fasudil as a disease-modifying drug for the treatment of PD and other synucleinopathies.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1186/s40478-016-0310-y
- Canonical
- link ↗
- Fetched
- 2026-10-29 MST
Cite this
APA
Tatenhorst, L., Eckermann, K., Dambeck, V., Fonseca‐Ornelas, L., Walle, H., Fonseca, T.L.D., Koch, J.C., Becker, S., Tönges, L., Bähr, M., Outeiro, T.F., Zweckstetter, M., & Lingor, P. (2016). Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease. <em>Acta Neuropathologica Communications</em>. https://doi.org/10.1186/s40478-016-0310-y
Vancouver
Tatenhorst L, Eckermann K, Dambeck V, Fonseca‐Ornelas L, Walle H, Fonseca TLD, et al. Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease. Acta Neuropathologica Communications. 2016. doi:10.1186/s40478-016-0310-y.
BibTeX
@article{lars2016Fasudi,
title = {Fasudil attenuates aggregation of α-synuclein in models of Parkinson’s disease},
author = {Lars Tatenhorst and Katrin Eckermann and Vivian Dambeck and Luis Fonseca‐Ornelas and Hagen Walle and Tomás Lopes da Fonseca and Jan Christoph Koch and Stefan Becker and Lars Tönges and Mathias Bähr and Tiago F. Outeiro and Markus Zweckstetter and Paul Lingor},
journal = {Acta Neuropathologica Communications},
year = {2016},
doi = {10.1186/s40478-016-0310-y},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Translational Neurodegeneration 2018
Open access · CC-BY
Age-dependent alpha-synuclein accumulation and aggregation in the colon of a transgenic mouse model of Parkinson’s disease
American Journal of Analytical Chemistry 2024
Open access · CC-BY
The Application of Analytical Techniques to Alpha-Synuclein in Parkinson’s Disease
Scientific Reports 2018
Open access · CC-BY
The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson’s disease
International Journal of Molecular Sciences 2020
Open access · CC-BY
The Role of α-Synuclein Oligomers in Parkinson’s Disease
Biomolecules 2014
Open access · CC-BY
Interactions between Calcium and Alpha-Synuclein in Neurodegeneration
Journal of Neurochemistry 2024
Open access · CC-BY